Ross Weinreb

Stock Analyst at Goldman Sachs

(n/a)
# 5,045
Out of 5,090 analysts
3
Total ratings
n/a
Success rate
-45.51%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Ross Weinreb

Relmada Therapeutics
Mar 24, 2022
Maintains: Buy
Price Target: $69$53
Current: $4.24
Upside: +1,150.00%